Podcasts about radiation oncology

In this episode of the ACRO podcast CURiE edition, CURiE Channel Editor Dr. Jessica Schuster speaks with author Dr. Shearwood McClelland, III about his published article, "Early Implementation of the Navigator-Assisted Hypofractionation (NAVAH) Program in Hispanic-American Breast Cancer Patients." Contemporary Updates: Radiotherapy Innovation & Evidence (CURiE) is the official publication platform of the American College of Radiation Oncology through the Cureus Journal of Medical Science.Read the article here: https://www.cureus.com/articles/363179-early-implementation-of-the-navigator-assisted-hypofractionation-navah-program-in-hispanic-american-breast-cancer-patients#!/

Radiation Therapy can seem daunting, but it doesn't have to be. Tune in to TALRadio English on Spotify & Apple Podcasts for a compelling interview with Dr. K.C. Goutham Reddy, Senior Consultant Oncologist and Founder & Managing Director of Cancer Shield Pvt Ltd. With a rich background in Medical Oncology, Radiation Oncology, and Palliative Care, Dr. Reddy shares valuable insights into the role of radiation therapy in cancer treatment, addressing common myths, clinical facts, and patient-centered approaches. Hosted by Suhasini, this episode offers clarity and confidence to those facing cancer.Host : SuhasiniGuest : K.C.Goutham ReddyYou Can Reach K.C.Goutham Reddy @linkedin.com/in/k-c-goutham-reddy-534b183b#TALRadioEnglish #CancerCare #RadiationTherapy #Oncology #HealthcareLeadership #PatientSupport #TALHospitals #MedicalOncology #PalliativeCare #CancerAwareness #HolisticHealing #ClinicalInsight #TouchALife #TALRadio

Host: Gerard A. Silvestri MD, MS, Master FCCP Guest: Anurag Singh, MD Guest: Adam H. Fox, MD, MSc Guest: Mariam Alexander, MD, PhD Despite the typically poor prognosis of extensive-stage small cell lung cancer, recent advancements are reshaping clinical perspectives on treatment. New and emerging options show promise for prolonged survival and improved quality of life. Join Drs. Gerard Silvestri, Adam Fox, Mariam Alexander, and Anurag Singh as they discuss how the therapeutic landscape is evolving for these patients. Silvestri is a pulmonologist and the Hillenbrand Professor of Thoracic Oncology at the Medical University of South Carolina. Dr. Fox is a pulmonologist and Assistant Professor of Medicine at the Medical University of South Carolina. Dr. Alexander is a medical oncologist and Assistant Professor of Medicine at the Medical University of South Carolina. Dr. Singh is a Professor of Radiation Oncology and the Director of Radiation Research at the Roswell Park Cancer Center in New York. This program is produced in partnership with the American College of Chest Physicians and is sponsored by AstraZeneca.

Host: Gerard A. Silvestri MD, MS, Master FCCP Guest: Anurag Singh, MD Guest: Adam H. Fox, MD, MSc Guest: Mariam Alexander, MD, PhD Recent therapeutic advances are reshaping our approach to limited-stage small cell lung cancer. In this multidisciplinary discussion, Dr. Gerard Silvestri sits down with Drs. Adam Fox, Mariam Alexander, and Anurag Singh to explore the evolving standard of care and practical considerations for timely and effective care. Dr. Silvestri is a pulmonologist and the Hillenbrand Professor of Thoracic Oncology at the Medical University of South Carolina. Dr. Fox is a pulmonologist and Assistant Professor of Medicine at the Medical University of South Carolina. Dr. Alexander is a medical oncologist and Assistant Professor of Medicine at the Medical University of South Carolina. Dr. Singh is a Professor of Radiation Oncology and the Director of Radiation Research at the Roswell Park Cancer Center in New York. This program is produced in partnership with the American College of Chest Physicians and is sponsored by AstraZeneca.

In this episode, Ayesha speaks with Ebrahim S. Delpassand, MD, Founder and CEO of RadioMedix, a company developing innovative radiopharmaceuticals for cancer diagnosis, monitoring and treatment. With a focus on both PET imaging and therapeutic radiopharmaceuticals labeled with alpha and beta emitters, RadioMedix is helping to shape the future of precision oncology. Dr. Delpassand brings a wealth of expertise as a board-certified nuclear medicine physician and a seasoned healthcare entrepreneur. He previously served as Deputy Chair and Chief of Clinical Nuclear Medicine at MD Anderson Cancer Center and is the Founder and Chairman of Excel Diagnostics & Nuclear Oncology Center. In addition to leading RadioMedix, he holds adjunct professorships in Radiation Oncology at the University of Texas and in Nuclear Medicine at Baylor College of Medicine. As a principal investigator and sponsor of five active INDs, Dr. Delpassand is a leader in clinical nuclear medicine research and translational drug development. He also co-founded Infinity Care and Infinity Infusion Care, successfully guiding the latter to acquisition by Curative Healthcare in 2002. Tune into the episode to hear Dr. Delpassand discuss the expanding role of radiopharmaceuticals in oncology, the challenges of developing theranostic agents and how his clinical and entrepreneurial background has shaped his vision for advancing nuclear medicine. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

On this week's show, your host, Justin Mog, scrubs your aural environment of all toxins with two colleagues from the University of Louisville's Center for Integrative Environmental Health Science (CIEHS): Cat Aiton, MSW, is the Community Resource Coordinator for the Community Engagement Core of CIEHS, and Sarah Jump is the Communications & Marketing Specialist. Learn more about the Center at https://louisville.edu/ciehs On the show, we discuss what environmental health is and how we all play a role in either advancing it or detracting from it. We share some practical tips for keeping yourself, your family, and your entire community healthy in the face of a world of dangerous toxins and pollutants. We talk about how the Center is working to reach young people with empowering messages and walking the talk with more sustainable give-aways. You'll also learn about an upcoming Conference for Advancing Participatory Sciences and the importance of Report Back strategies for sharing findings with communities in a language that is meaningful to them. We'll also tell you all about the upcoming Environmental Health Youth Academy that the Center is organizing this summer (https://events.louisville.edu/event/2025-ciehs-cec-environmental-health-summer-youth-academy). The deadline to apply for this free summer series in June 16th and it is open to all high school sophomores, juniors, and seniors. CIEHS will host a two-week Youth Academy focused on environmental health in Louisville, July 14-24! At the end of the academy, participants will receive a certificate and a letter of completion (plus some free sustainable swag), making this a valuable addition to college or job applications. We have limited spots available—only 20 students will be accepted for this exclusive summer program, where you will learn directly from environmental health experts. Applications must be submitted by June 16th! Learn more and apply at https://louisville.edu/ciehs. The schedule for the Youth Academy is as follows: July 14 (In Person with lunch): Introduction to Environmental Health Banrida Wahlang, PhD, UofL Gastroenterology, Hepatology and Nutrition Lu Cai, MD, PhD, UofL Pediatrics, Radiation Oncology, and Pharmacology & Toxicology July 15 (Virtual): Air Quality and Health Petra Haberzettl, PhD, UofL Medicine, Diabetes & Obesity Center July 16 (Virtual): Water & Health Mayukh Banerjee, PhD, UofL Pharmacology & Toxicology July 17 (In Person with lunch): Community-Led Science Ted Smith, PhD, UofL Medicine and Pharmacology/Toxicology Rachel Neal, PhD, UofL Biology Luz Huntington-Moskos, PhD, RN, CPN, FAAN, UofL School of Nursing July 21 (Virtual): Energy & Health Sumedha Rao, Mayor's Office of Sustainability July 22 (Virtual): Mapping the Issues Charlie Zhang, PhD, UofL Geographic & Environmental Sciences, DJ Biddle, Director and Senior Lecturer, UofL Center for Geographic Information System Laura Krauser, UofL's Geographic Information Sciences Research Coordinator July 23 (Virtual): Communicating Sustainability Brent Fryrear, UofL Sustainability Council July 24 (In Person with lunch): Policy Advocacy and Storytelling Dr. Tony Arnold, UofL Law, Urban and Public Affairs, Resilience Justice Project Angela Story, PhD, UofL Anthropology and Director of Anne Braden Institute As always, our feature is followed by your community action calendar for the week, so get your calendars out and get ready to take action for sustainability NOW! Sustainability Now! is hosted by Dr. Justin Mog and airs on Forward Radio, 106.5fm, WFMP-LP Louisville, every Monday at 6pm and repeats Tuesdays at 12am and 10am. Find us at http://forwardradio.org The music in this podcast is courtesy of the local band Appalatin and is used by permission. Explore their delightful music at http://appalatin.com

Are you or a loved one facing a diagnosis of bladder cancer, melanoma, or skin cancer? Tune in to this essential episode of Navigating Cancer TOGETHER for expert guidance and compassionate insights. Join host Talaya Dendy as she welcomes back Dr. Thomas Eanelli, a highly respected radiation oncologist based in New York. We also feature Angel Santana, co-host of The CROC Podcast, sharing powerful motivational perspectives. In observance of May Cancer Awareness, this special episode dives into critical aspects of three specific cancers: bladder, melanoma, and skin cancer. Dr. Eanelli provides invaluable medical expertise on the latest cancer treatments, diagnosis, and management of these diseases. Angel Santana offers heartfelt inspiration and emphasizes the power of support and positivity throughout the cancer journey. This episode is packed with vital information and moving stories to offer hope and guidance for anyone navigating cancer.

Dr. Mamta Singhvi defies every stereotype you thought you knew. A Trump supporter with degrees from UCLA and Harvard. Board Certified in Radiation Oncology & Integrative Medicine a scientist who speaks openly about miracles. The daughter of Indian immigrants who advocates for stronger borders. She graduated summa cum laude from UCLA, became the youngest graduate in her medical school class, earned a Masters from Harvard School of Public Health, and has practiced in rural America while jetting to over 40 countries. She's visited India more than 50 times- where she received her Yoga teacher training and provided free medical care from El Salvador to Ethiopia. During COVID, while most physicians fell in line, she took a public stand against vaccine mandates. She has a background modeling & pageantry, was selected to serve as ambassador for global clothing brand Bebe, an experience she parlayed into a national cancer awareness campaign. We talk about the rise in cancer, true healing, spirituality and achieving freedom from systems designed to keep us sick and dependent. Chapters00:00 Introduction to Dr. Mamta Singhvi02:50 Embracing Multidimensionality06:43 The Struggle for Authenticity10:11 Facing Dark Fears18:39 Integrative Oncology: A New Perspective30:00 The Role of Faith in Healing39:48 The Intersection of Science and Spirituality41:47 The Power of the Placebo Effect43:50 Spirituality and Health46:15 The Limitations of Western Medicine48:07 The Connection Between Spirituality and Healing51:05 Medical Freedom and the Healing Industry54:07 Embracing Mortality and Living Fully57:15 Ayurveda and Ancient Healing Practices01:01:04 The Role of Personalization in Medicine01:11:44 Rebuilding Trust in the Medical CommunityDr. Singhvi X AccountRADICALLY GENUINE PODCASTDr. Roger McFillin / Radically Genuine WebsiteYouTube @RadicallyGenuineDr. Roger McFillin (@DrMcFillin) / XSubstack | Radically Genuine | Dr. Roger McFillinInstagram @radicallygenuineContact Radically GenuineConscious Clinician CollectivePLEASE SUPPORT OUR PARTNERS15% Off Pure Spectrum CBD (Code: RadicallyGenuine)10% off Lovetuner click here

Check out this week's QuadCast as we highlight SRS vs. fSRS for hearing preservation in vestibular schwannomas, preoperative immunotherapy in HNSCC, and much more. Check out the website and subscribe to the newsletter! www.quadshotnews.com Founders & Lead Authors: Laura Dover & Caleb Dulaney Podcast Host: Sam Marcrom

Check out this week's QuadCast as we highlight the predictive abilities of AI for ADT duration in prostate cancer, how consolidative chemoRT benefits patients with unresectable gallbladder cancer, the benefits of immunotherapy in clear cell GYN cancer, and more. Check out the website and subscribe to the newsletter! www.quadshotnews.com Founders & Lead Authors: Laura Dover & Caleb Dulaney Podcast Host: Sam Marcrom

Editor in Chief Sue Yom hosts four of our artists – Jen Bellon, our journal's Art Editor, who was previously at Dana Farber Cancer Institute/Brigham & Women's Hospital, and now works as an independent art consultant; Annie Lavigne, Assistant Professor of Radiation Oncology at Johns Hopkins University; Josh No, Attending Physician at Kaiser Permanente; and Tony Orlina, Lead Dosimetrist at Dana Farber Cancer Center. They discuss the role of art in their lives, stories of their Red Journal cover artworks, and what they see as the role of art in medicine.

Check out this week's QuadCast as we highlight PROSTOX's ability to predict late GU toxicity, why long course chemoradiation may be better than short course RT in rectal cancer, how to identify aggressive chromosomal alterations in meningiomas, and more. Check out the website and subscribe to the newsletter! www.quadshotnews.com Founders & Lead Authors: Laura Dover & Caleb Dulaney Podcast Host: Sam Marcrom

JCO PO author Dr. Timothy Showalter at Artera and University of Virginia shares insights into his JCO PO article, “Digital Pathology–Based Multimodal Artificial Intelligence Scores and Outcomes in a Randomized Phase III Trial in Men With Nonmetastatic Castration-Resistant Prostate Cancer” . Host Dr. Rafeh Naqash and Dr. Showalter discuss how multimodal AI as a prognostic marker in nonmetastatic castration-resistant prostate cancer may serve as a predictive biomarker with high-risk patients deriving the greatest benefit from treatment with apalutamide. TRANSCRIPT  Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations where we'll bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I'm your host, Dr. Rafeh Naqash, podcast Editor for JCO Precision Oncology and assistant professor at the OU Health Stephenson Cancer Center at the University of Oklahoma. Today, we are excited to be joined by Dr. Timothy Showalter, Chief Medical Officer at Artera and professor of Radiation Oncology at the University of Virginia and author of the JCO Precision Oncology article entitled, “Digital Pathology Based Multimodal Artificial Intelligence Scores and Outcomes in a Randomized Phase 3 Trial in Men with Non-Metastatic Castration Resistant Prostate Cancer.” At the time of this recording, our guest's disclosures will be linked in the transcript. Dr. Showalter, it's a pleasure to have you here today. Dr. Timothy Showalter: It's a pleasure to be here. Thanks for having me. Dr. Rafeh Naqash: I think this is going to be a very interesting discussion, not just from a biomarker perspective, but also in terms of how technologies have evolved and how we are trying to stratify patients, trying to escalate or deescalate treatments based on biomarkers. And this article is a good example of that. One of the things I do want to highlight as part of this article is that Dr. Felix Feng is the first author for this article. Unfortunately, Dr. Felix Feng passed away in December of 2024. He was a luminary in this field of prostate cancer research. He was also the Chair of the NRG GU Committee as well as Board of Directors for RTOG Foundation and has mentored a lot of individuals from what I have heard. I didn't know Dr. Feng but heard a lot about him from my GU colleagues. It's a huge loss for the community, but it was an interesting surprise for me when I saw his name on this article as I was reviewing it. Could you briefly talk about Dr. Feng for a minute and how you knew him and how he's been an asset to the field? Dr. Timothy Showalter: Yeah. I'm always happy to talk about Felix whenever there's an opportunity. You know, I was fortunate to know Felix Feng for about 20 years as we met during our residency programs through a career development workshop that we both attended and stayed close ever since. And you know, he's someone who made an impact on hundreds of lives of cancer researchers and other radiation oncologists and physicians in addition to the cancer patients he helped, either through direct clinical care or through his innovation. For this project in particular, I first became involved soon after Felix had co-founded Artera, which is, you know the company that developed this. And because Felix was such a prolific researcher, he was actually involved in this and this research project from all different angles, both from the multimodal digital pathology tool to the trial itself and being part of moving the field forward in that way. It's really great to be able to sort of celebrate a great example of Felix's legacy, which is team science, and really moving the field forward in terms of translational projects based on clinical trials. So, it's a great opportunity to highlight some of his work and I'm really happy to talk about it with you. Dr. Rafeh Naqash: Thanks, Tim. Definitely a huge loss for the scientific community. And I did see a while back that there was an international symposium organized, showcasing his work for him to talk about his journey last year where more than 200, 250 people from around the globe actually attended that. That speaks volumes to the kind of impact he's had as an individual and impact he's had on the scientific side of things as well. Dr. Timothy Showalter: Yes. And we just had the second annual Feng Symposium the day before ASCO GU this year with, again, a great turnout and some great science highlighted, as well as a real focus on mentorship and team science and collaboration. Dr. Rafeh Naqash: Thank you so much for telling us all about that. Now going to what you guys published in JCO Precision Oncology, which is this article on using a biomarker approach to stratify non-metastatic prostate cancer using this artificial intelligence based H&E score. Could you tell us the background for what started off this project? And I see there is a clinical trial data set that you guys have used, but there's probably some background to how this score or how this technology came into being. So, could you superficially give us an idea of how that started? Dr. Timothy Showalter: Sure. So, the multimodal AI score was first published in a peer reviewed journal back in 2022 and the test was originally developed through a collaboration with the Radiation Therapy Oncology Group or Energy Oncology Prostate Cancer Research Team. The original publication describes development and validation of a risk stratification tool designed to predict distant metastasis and prostate cancer specific mortality for men with localized prostate cancer. And the first validation was in men who were treated with definitive radiation therapy. There have been subsequent publications in that context and there's a set of algorithms that have been validated in localized prostate cancer and there's a test that's listed on NCCN guidelines based on that technology. The genesis for this paper was really looking at extending that risk stratification tool that was developed in localized prostate cancer to see if it could one, validate in a non-metastatic castrate refractory prostate cancer population for patients enrolled on the SPARTAN trial. And two, whether there was a potential role for the test output in terms of predicting benefit from apalutamide for patients with non-metastatic prostate cancer. For patients who are enrolled on the SPARTAN study, almost 40% of them had H&E stain biopsy slide material available and were eligible to be included in this study. Dr. Rafeh Naqash: Going a step back to how prostate cancer, perhaps on the diagnostic side using the pathology images is different as you guys have Gleason scoring, which to the best of my knowledge is not necessarily something that most other tumor types use. Maybe Ki-67 is somewhat of a comparison in some of the neuroendocrine cancers where high Ki-67 correlates with aggressive biology for prognosis. And similarly high Gleason scores, as we know for some of the trainees, correlates with poor prognosis. So, was the idea behind this based on trying to stratify or sub-stratify Gleason scoring further, where you may not necessarily know what to do with the intermediate high Gleason score individual tumor tissues? Dr. Timothy Showalter: Well, yeah. I mean, Gleason score is a really powerful risk stratification tool. As you know, our clinical risk groupings are really anchored to Gleason scores as an important driver for that. And while that's a powerful tool, I think, you know, some of the original recognition for applying computer vision AI into this context is that there are likely many other features located in the morphology that can be used to build a prognostic model. Going back to the genesis of the discovery project for the multimodal AI model, I think Felix Feng would have described it as doing with digital pathology and computer vision AI what can otherwise be done with gene expression testing. You know, he would have approached it from a genomic perspective. That's what the idea was. So, it's along the line of what you're saying, which is to think about assigning a stronger Gleason score. But I think really more broadly, the motivation was to come up with an advanced complementary risk stratification tool that can be used in conjunction with clinical risk factors to help make better therapy recommendations potentially. So that was the motivation behind it. Dr. Rafeh Naqash: Sure. And one of the, I think, other important teaching points we try to think about, trainees of course, who are listening to this podcast, is trying to differentiate between prognostic and predictive scores. So, highlighting the results that you guys show in relation to the MMAI score, the digital pathology score, and outcomes as far as survival as well as outcomes in general, could you try to help the listeners understand the difference between the prognostic aspect of this test and the predictive aspect of this test? Dr. Timothy Showalter: So let me recap for the listeners what we found in the study and how it kind of fits into the prognostic and the predictive insights. So, one, you know, as I mentioned before, this is ultimately a model that was developed and validated for localized prostate cancer for risk stratification. So, first, the team looked at whether that same tool developed in localized prostate cancer serves as a prognostic tool in non-metastatic castrate-refractory prostate cancer. So, we applied the tool as it was previously developed and identified that about 2/3 of patients on the SPARTAN trial that had specimens available for analysis qualified as high risk and 1/3 of patients as either intermediate or low risk, which we called in the paper ‘non-high risk'. And we're able to show that the multimodal AI score, which ranges from 0 to 1, and risk group, was associated with metastasis free survival time to second progression or PFS 2 and overall survival. And so that shows that it performs as a prognostic tool in this setting. And this paper was the first validation of this tool in non-metastatic castrate-refractory prostate cancer. So, what that means to trainees is basically it helps you understand how aggressive that cancer is or better stratify the risk of progression over time. So that's the prognostic performance. Dr. Rafeh Naqash: Thank you for trying to explain that. It's always useful to get an example and understand the difference between prognostic and predictive. Now again, going back to the technology, which obviously is way more complicated than the four letter word MMAI, I per se haven't necessarily done research in this space, but I've collaborated with some individuals who've done digital pathology assessments, and one of the projects we worked on was TIL estimation and immune checkpoint related adverse events using some correlation and something that one of my collaborators had sent to me when we were working on this project as part of this H&E slide digitalization, you need color deconvolution, you need segmentation cell profiling. Superficially, is that something that was done as part of development of this MMAI score as well? Dr. Timothy Showalter You need a ground truth, right? So, you need to train your model to predict whatever the outcome is. You know, if you're designing an AI algorithm for Ki-67 or something I think you mentioned before, you would need to have a set of Ki-67 scores and train your models to create those scores. In this case, the clinical annotation for how we develop the multimodal AI algorithm is the clinical endpoints. So going back to how this tool was developed, the computer vision AI model is interpreting a set of features on the scan and what it's trying to do is identify high risk features and make a map that would ultimately predict clinical outcomes. So, it's a little bit different than the many digital pathology algorithms where the AI is being trained to predict a particular morphological finding. In this case, the ground truth that the model is trained to predict is the clinical outcome. Dr. Rafeh Naqash: Sure. And from what you explained earlier, obviously, tumors that had a high MMAI score were the ones that were benefiting the most from the ADT plus the applausive. Is this specific for this androgen receptor inhibitor or is it interchangeable with other inhibitors that are currently approved? Dr. Timothy Showalter: That's a great question and we don't know yet. So, as you're alluding to, we did find that the MMAI risk score was predictive for benefit from apalutamide and so it met the statistical definition of having a significant interaction p value so we can call it a predictive performance. And so far, we've only looked in this population for apalutamide. I think you're raising a really interesting point, which is the next question is, is this generalizable to other androgen receptor inhibitors? There will be future research looking at that, but I think it's too early to say. Just for summary, I think I mentioned before, there are about 40% of patients enrolled on the SPARTAN study had specimens available for inclusion in this analysis. So, the SPARTAN study did show in the entire clinical trial set that patients with non-metastatic castrate-refractory prostate cancer benefited from apalutamide. The current study did show that there seems to be a larger magnitude of benefit for those patients who are multimodal AI high risk scores. And I think that's very interesting research and suggests that there's some interaction there. But I certainly would want to emphasize that we have not shown that patients with intermediate or low risk don't benefit from apalutamide. I think we can say that the original study showed that that trial showed a benefit and that we've got this interesting story with multimodal AI as well. Dr. Rafeh Naqash: Sure. And I think from a similar comparison, ctDNA where ctDNA shows prognostic aspects, I treat people with lung cancer especially, and if you're ctDNA positive at a 3 to 4-month period, likely chances of you having a shorter disease-free interval is higher. Same thing I think for colorectal cancers. And now there are studies that are using ctDNA as an integral biomarker to stratify patients positive/negative and then decide on escalation/de-escalation of treatment. So, using a similar approach, is there something that is being done in the context of the H&E based stratification to de-intensify or intensify treatments based on this approach? Dr. Timothy Showalter: You're hitting right on the point in the most promising direction. You know, as we pointed out in the manuscript, one of the most exciting areas as a next step for this is to use a tool like this for stratification for prospective trials. The multimodal AI test is not being used currently in clinical trials of non-metastatic castrate-refractory prostate cancer, which is a disease setting for this paper. There are other trials that are in development or currently accruing where multimodal AI stratification approach is being taken, where you see among the high-risk scores, at least in the postoperative setting for a clinical trial that's open right now, high risk score patients are being randomized to basically a treatment intensification question. And then the multimodal AI low risk patients are being randomized to a de-intensification experimental arm where less androgen deprivation therapy is being given. So, I think it's a really promising area to see, and I think what has been shown is that this tool has been validated really across the disease continuum. And so, I think there are opportunities to do that in multiple clinical scenarios. Dr. Rafeh Naqash: Then moving on to the technological advancements, very fascinating how we've kind of evolved over the last 10 years perhaps, from DNA based biomarkers to RNA expression and now H&E. And when you look at cost savings, if you were to think of H&E as a simpler, easier methodology, perhaps, with the limitations that centers need to digitalize their slides, probably will have more cost savings. But in your experience, as you've tried to navigate this H&E aspect of trying to either develop the model or validate the model, what are some of the logistics that you've experienced can be a challenge? As we evolve in this biomarker space, how can centers try to tackle those challenges early on in terms of digitalizing data, whether it's simple data or slides for that matter? Dr. Timothy Showalter: I think there's two main areas to cover. One, I think that the push towards digitalization is going to be, I think, really driven by increasing availability and access to augmentative technologies like this multimodal AI technology where it's really adding some sort of a clinical insight beyond what is going to be generated through routine human diagnostic pathology. I think that when you can get these sorts of algorithms for patient care and have them so readily accessible with a fast turnaround time, I think that's really going to drive the field forward. Right now, in the United States, the latest data I've seen is that less than 10% of pathology labs have gone digital. So, we're still at an early stage in that. I hope that this test and similar ones are part of that push to go more digital. The other, I think, more interesting challenge that's a technical challenge but isn't about necessarily how you collect the data, but it certainly creates data volume challenges, is how do you deal with image robustness and sort of translating these tools into routine real-world settings. And as you can imagine, there's a lot of variation for staining protocols, intensity scanner variations, all these things that can affect the reliability of your test. And at least for this research group that I'm a part of that has developed this multimodal AI tool can tell you that the development is sophisticated, but very data and energy intensive in terms of how to deal with making a tool that can be consistent across a whole range of image parameters. And so that presents its own challenges for dealing with a large amount of compute time and AI cycles to make robust algorithms like that. And practically speaking, I think moving into other diseases and making this widely available, the size of data required and the amount of cloud compute time will be a real challenge. Dr. Rafeh Naqash: Thank you for summarizing. I can say that definitely, you know, this is maybe a small step in prostate cancer biomarker research, but perhaps a big step in the overall landscape of biomarker research in general. So definitely very interesting. Now, moving on to the next part of the discussion is more about you as a researcher, as an individual, your career path, if you can summarize that for us. And more interestingly, this intersection between being part of industry as well as academia for perhaps some of the listeners, trainees who might be thinking about what path they want to choose. Dr. Timothy Showalter: Sure. So, as you may know, I'm a professor at the University of Virginia and I climbed the academic ladder and had a full research grant program and thought I'd be in academia forever. And my story is that along the way, I kind of by accident ended up founding a medical device company that was called Advaray and that was related to NCI SBIR funding. And I found myself as a company founder and ultimately in that process, I started to learn about the opportunity to make an impact by being an innovator within the industry space. And that was really the starting point for me. About four years ago, soon after Felix Feng co-founded Artera, he called me and told me that he needed me to join the company. For those who were lucky to know Felix well, at that very moment, it was inevitable that I was going to join Artera and be a part of this. He was just so persuasive. So, I will say, you know, from my experience of being sort of in between the academic and industry area, it's been a really great opportunity for me to enter a space where there's another way of making an impact within cancer care. I've gotten to work with top notch collaborators, work on great science, and be part of a team that's growing a company that can make technology like this available. Dr. Rafeh Naqash: Thank you so much, Tim, for sharing some of those thoughts and insights. We really appreciate you discussing this very interesting work with us and also appreciate you submitting this to JCO Precision Oncology and hopefully we'll see more of this as this space evolves and maybe perhaps bigger more better validation studies in the context of this test. Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcast.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Editor in Chief Dr. Sue Yom hosts a discussion on the role of radiation for gallbladder cancer, as it is managed in India versus the U.S. Guests are Section Editor Dr. Michael Chuong, Vice Chair and Medical Director of Radiation Oncology at Miami Cancer Institute, and Dr. Sushma Agrawal, Professor from the Department of Radiotherapy at Sanjay Gandhi Post Graduate Institute of Medical Sciences in Lacknow, India, RACE-GB Principal Investigator, and first author of the primary trial report, A Randomized Study of Consolidation Chemoradiotherapy Versus Observation After First-line Chemotherapy in Advanced Gallbladder Cancers: RACE-GB Study.

Veterinary oncology today makes use of increasingly sophisticated tools and methods for treating cancer…

Veterinary oncology today makes use of increasingly sophisticated tools and methods for treating cancer in pets. In addition to surgery and medical therapy, or chemotherapy, radiation oncology is a veterinary specialty...

Check out the this week's QuadCast as we highlight omission of surgery in breast cancer patients, best management of small cell lung cancer, adaptive radiation for cervical cancer, the best approach for prostate brachytherapy boost, and more. Check out the website and subscribe to the newsletter! www.quadshotnews.com Founders & Lead Authors: Laura Dover & Caleb Dulaney Podcast Host: Sam Marcrom

CancerNetwork® visited Sibley Memorial Hospital of Johns Hopkins Medicine to speak with a variety of experts about therapeutic advancements and ongoing research initiatives across several different cancer fields. As part of each discussion, clinicians highlighted how collaboration across different departments has positively impacted treatment planning, decision-making, and outcomes at their institution. These experts included the following: ·      Rachit Kumar, MD, an assistant professor of Radiation Oncology and Molecular Radiation Sciences at Johns Hopkins School of Medicine and a radiation oncologist specializing in genitourinary and gastrointestinal cancers at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center for Sibley Memorial Hospital and Suburban Hospital; ·      Michael J. Pishvaian, MD, PhD, director of Gastrointestinal, Developmental Therapeutics, and Clinical Research Programs, and associate professor of Oncology at Johns Hopkins School of Medicine; ·      Nina Wagner-Johnston, MD, a professor of Oncology and the director of Lymphoma Drug Development at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, director of Hematologic Malignancies National Capital Region, and co-director of Clinical Research for Hematologic Malignancies; ·      Valerie Lee, MD, an assistant professor of Oncology at Johns Hopkins University School of Medicine and a medical oncologist at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center at Sibley Memorial Hospital; ·      Armine Smith, MD, the director of urologic oncology at the Sidney Kimmel Comprehensive Cancer Center at Sibley Memorial Hospital, and an assistant clinical professor of Urology at the Brady Urological Institute of Johns Hopkins University School of Medicine; ·      Pouneh Razavi, MD, the director for Breast Imaging in the National Capital Region and an instructor in Radiology and Radiological Science; ·      and Curtiland Deville Jr., MD, medical director of the Johns Hopkins Proton Therapy Center and clinical director of Radiation Oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center at Sibley Memorial Hospital. Altogether, their insights demonstrated how multidisciplinary teamwork has improved outcomes ranging from patient survival to healthcare resource utilization across a wide range of diseases including breast cancer, gastrointestinal cancer, genitourinary cancer, hematologic malignancies, and others.

“There have been many changes since the '70s that have shaped the nurse's role in administering chemo, and in supporting patients. The major change early on was the transition from that of nurses mixing chemo to that of pharmacists. Regulatory agencies like NIOSH and OSHA defined chemotherapy as hazardous drugs, and professional organizations became involved, leading to the publication of the joint ASCO and ONS Standards of Safe Handling,” ONS member Scarlott Mueller, MPH, RN, FAAN, secretary of the American Cancer Society Cancer Action Network Board and member of the Oncology Nursing Foundation Capital Campaign Cabinet, told Darcy Burbage, DNP, RN, AOCN®, CBCN®, ONS member and chair of the ONS 50th Anniversary Committee during a conversation about the evolution of chemotherapy treatment. Along with Mueller, Burbage spoke with John Hillson, DNP, NP, Mary Anderson, BSN, RN, OCN®, and Kathleen Shannon-Dorcy, PhD, RN, FAAN, about the changes in radiation, oral chemotherapy, and cellular therapy treatments they have witnessed during their careers. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Episode Notes  This episode is not eligible for NCPD. ONS Podcast™ episodes: 50th anniversary series Episode 330: Stay Up to Date on Safe Handling of Hazardous Drugs Episode 59: Blood and Marrow Transplant Nursing Episode 16: Navigating the Challenges of Oral Chemotherapy ONS Voice article:Safe Handling—We've Come a Long Way, Baby! ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Hematopoietic Stem Cell Transplantation: A Manual for Nursing Practice (third edition) Oncology Nurse Navigation: Delivering Patient-Centered Care Across the Continuum (second edition) Safe Handling of Hazardous Drugs (fourth edition) ONS courses: ONS Hematopoietic Stem Cell Transplantation™ ONS/ONCC® Chemotherapy Immunotherapy Certificate™ ONS/ONCC® Radiation Therapy Certificate™ Safe Handling Basics Oral Anticancer Medication Toolkit Oral Anticancer Medication Care Compass Patient education guides created as a collaboration between ONS, HOPA, NCODA, and the Association of Community Cancer Centers: IV Cancer Treatment Education Sheets Oral Chemotherapy Education Sheets Connie Henke Yarbro Oncology Nursing History Center To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode Hillson: “I remember as a new grad, from back in '98, walking up to the oncology floor. We had patients with pink labels on the chart and that was the radiation oncology service. I hadn't heard of such a thing before. … I'd gone through nursing school and hospital orientation and unit orientation without ever hearing of these therapies. At the time, both the management and the union had no interest in specialist nurses, and the really weren't any books that were targeting the role. And it was very isolating and frightening. I was very glad to find ONS when I moved to the U.S. Right now, the Oncology Nursing Society Manual for Radiation Oncology, Nursing Practice, and Education, it's in its fifth edition and a sixth is underway. There's nothing else like it. Most books are very much geared towards other professions.” TS 5:34 Mueller: “We mixed our chemo in a very small medication room on the unit, under a horizontal laminar flow hood, which we later discovered should have been a vertical laminar flow hood. Initially, we did not use any personal protective equipment. I remember mixing drugs like bleomycin and getting a little spray that from the vial onto my face. And to this day, I still have a few facial blemishes from that.” TS 14:28 Anderson: “As the increasing number of these actionable mutations continue to grow, so will the number of oral anticancer medications that patients are going to be taking. And we are already seeing that there's multiple combination regimens and complex schedules that the patients have to take. So this role the oral oncolytic nurse and the nursing role, like you said, it cannot be owned by one individual or discipline. So it's not a pharmacist; the pharmacies aren't owning this. The nurses are not owning this. It takes a village.” TS 32:12 Shannon-Dorcy: Then as immunotherapy comes into the picture, we start to learn about [cytokine release syndrome]. All of a sudden, we had no concept that this was a deadly consequence. ONS was on the front lines, convening people across the country together so we could speak to the investigative work with science and find ways that we could intervene, how we can look for signs of it early on with handwriting testing.” TS 39:58

Miriam "Mimi" Knoll, M.D., DABR, is the co-founder and CEO of JOWMA and a radiation oncologist at Northwell Health in New York.Dr. Knoll earned her medical degree from New York University School of Medicine and completed her radiation oncology training at Mount Sinai Medical Center in New York.She serves as a section editor for Advances in Radiation Oncology, the peer-reviewed journal of the American Society of Radiation Oncology (ASTRO), and is an active volunteer with ASCO, ASTRO, NRG, and the RTOG Foundation.An international speaker and researcher, Dr. Knoll focuses on the medical workforce, women in medicine, and social media in medicine. She is a Forbes Healthcare contributor and writes for the American Society of Clinical Oncology (ASCO) Connection and various other media outlets.You can follow her on Twitter @MKnoll_MD and on Instagram @Dr.Mimi.K.Sponsor the JOWMA Podcast! Email digitalcontent@jowma.orgBecome a JOWMA Member! www.jowma.org Follow us on Instagram! www.instagram.com/JOWMA_org Follow us on Twitter! www.twitter.com/JOWMA_med Follow us on Facebook! https://www.facebook.com/JOWMAorgStay up-to-date with JOWMA news! Sign up for the JOWMA newsletter! https://jowma.us6.list-manage.com/subscribe?u=9b4e9beb287874f9dc7f80289&id=ea3ef44644&mc_cid=dfb442d2a7&mc_eid=e9eee6e41e

In this episode of GynoCurious, Dr. Amy Novatt welcomes Dr. Beth Tapen, a radiation oncologist based in Northern California, to discuss the intricacies of radiation oncology. They delve into the history and practice of using radiation to treat various cancers, explaining how this powerful yet paradoxical tool has evolved since its inception in the late 19th century. Dr. Tapen shares her journey into the medical field, highlighting experiences from her training and the challenges she faced, including a significant crossroad in her career path and a difficult experience with misogyny in a residency program. The conversation explores the complexities and technological advances in radiation therapy, particularly as it applies to female pelvic and breast cancers. Dr. Tapen details the multi-disciplinary approach involved in planning radiation treatments, including the importance of understanding cancer biology, human physiology, and technological aspects of treatment. She describes the patient experience, from initial consultation through to the administration of treatment, emphasizing the meticulous care that goes into mitigating side effects and customizing the approach based on individual patient needs. Towards the end of the episode, the discussion shifts to the emotional and psychological aspects of oncology care. Dr. Novatt and Dr. Tapen stress the importance of informed consent, the patient's role in their own treatment decisions, and the critical impact of clinical trials on improving cancer care. Questions of comments? Call 845-307-7446 or email comments@radiofreerhinecliff.org Produced by Jennifer Hammoud and Matty Rosenberg @ Radio Free Rhiniecliff

Check out this week's QuadCast where we highlight the link between dental hygiene and oral mucositis risk, the optimal timing of post-treatment PSMA PET scans, the impressive impact of immunotherapy in MSI-high colorectal cancer, and more. Check out the website and subscribe to the newsletter! www.quadshotnews.com Founders & Lead Authors: Laura Dover & Caleb Dulaney Podcast Host: Sam Marcrom

Professor Amar U. Kishan (Department of Radiation Oncology, University of California, Los Angeles, CA, USA) discusses his paper on HYpofractionateD RAdiotherapy for Prostate Cancer (HYDRA): An Individual Patient Data Meta-Analysis of Randomised Trials in the MARCAP Consortium.Read the full article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00034-8/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanoncTell us what you thought about this episodeContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

The first two episodes in this Healthcare is Hard podcast series on “Opportunities in Oncology” explored the relationship between academic medical centers and community care, with guests Dr. Stephen Schleicher from Tennessee Oncology, and Dr. Harlan Levine from City of Hope. For the third and final episode in the series, Dr. Daphne Haas-Kogan joined Keith Figlioli for a conversation that dives more deeply into patient care, innovations in care delivery and the opportunities for entrepreneurs.Dr. Haas-Kogan is Chair of the Department of Radiation Oncology at Mass General Hospital, Brigham and Women's Hospital, and Boston Children's Hospital. She is also the Willem and Corrie Hees Family Professor of Radiation Oncology at Harvard Medical School.Dr. Haas-Kogan received her undergraduate degree in biochemistry and molecular biology from Harvard University and her medical degree at UCSF. She completed her residency in radiation oncology at UCSF in 1997 and became vice-chair for research at UCSF in 2003, and educational program director in 2008. Dr. Haas-Kogan's laboratory research focuses on molecular underpinnings of brain tumors and pediatric cancers. She leads large multi-institutional initiatives funded by NIH/NCI, philanthropic organizations, and industry collaborators.For this episode of Healthcare is Hard, some of the topics Dr. Haas-Kogan discussed with Keith include:The collaborative approach to care. Dr. Haas-Kogan talked about how most people with cancer struggle with many other medical issues – some predating cancer diagnosis, some precipitated by the treatment itself – and how several care teams are required to treat the patient wholistically. She also discussed how important it is for academic medical centers and community hospitals to work together, the responsibilities each holds to the patient, and the goal of making sure patients receive the same exact care regardless of location.The precision of radiation oncology. There are generally three pillars of cancer treatment. The first is surgery to remove tumors, the second is medication to kill cancer cells with drugs, and the third is radiation therapy to destroy cancer cells. Dr. Haas-Kogan described how radiation oncology is, in many ways, a combination of surgical oncology and medical oncology. It requires the precision of surgery – especially when treating a tumor close to critical structures like the brain stem or spinal cord – but can also be applied in a single day or over the course of weeks, similar to medication. She discussed how this allows for unique collaboration between academic researchers and community physicians, along with opportunities for creative workforce solutions.AI in oncology. The impact artificial intelligence has already had on oncology would have been unimaginable five or 10 years ago, and Dr. Haas-Kogan says the opportunities for entrepreneurs in the space are huge. As an example of the impact AI has already made, she talked about how radiation oncologists traditionally spend hours defining exactly what they want treated and the dose of radiation required. But now, AI is doing most of that, saving physicians precious time. She talked about how medicine is an art and how treatment like this is very nuanced, so she very often makes changes after reviewing AI-generated recommendations. But she says advancements are coming quickly.To hear Dr. Haas-Kogan and Keith discuss these topics and more, listen to this episode of Healthcare is Hard: A Podcast for Insiders.

How This Is Building Me, hosted by world-renowned oncologist D. Ross Camidge, MD, PhD, is a podcast focused on the highs and lows, ups and downs of all those involved with cancer, cancer medicine, and cancer science across the full spectrum of life's experiences. In this episode, Dr Camidge sat down with Alexandra Rink, PhD, a medical physicist at Princess Margaret Cancer Centre; a clinician scientist at the Princess Margaret Research Institute; and an associate professor in the Departments of Radiation Oncology and Medical Biophysics at the University of Toronto in Canada. Drs Camidge and Rink discussed how Dr Rink's early career interest in forensics led her down the path toward becoming a medical physicist, how physics factor into radiation therapy delivery, and the importance of multidisciplinary collaboration to deliver optimal patient care.

ROCR is back. From accreditation traps to Congressional risks, this episode breaks down the data and delivers six bold fixes to save patient access. Tune in to hear why time's running out for Radiation Oncology's underdogs.OOTB is produced by Photon Media.Contact: jason@becktamd.com

Dr. Sue Yom, Editor in Chief, co-hosts with Dr. Lachlan McDowell, Consultant Radiation Oncologist at the Princess Alexandra Hospital in Queensland, Australia and our journal's Head and Neck Cancer Section Editor. Guests are Dr. Sean McBride, Radiation Oncologist at Memorial Sloan Kettering Cancer Center and Chief of External Beam Radiotherapy at the Manhattan site, who authored an editorial, Oligometastatic HNSCC: Is SABR the Solution?, and Dr. Juliette Thariat, Professor in Radiation Oncology at Cancer Center Baclesse in Normandy, France, Secrétaire Nationale at the GORTEC, and first author of our featured article, Survival Without Quality of Life Deterioration in the GORTEC 2014-04 "OMET" Randomized Phase 2 Trial in Patients with Head and Neck Cancer with Oligometastases using Stereotactic Ablative Radiation Therapy (SABR) alone or Chemotherapy and SABR.

In a recent episode of Oncology on the Go, several oncologists discussed the impact of the COVID-19 pandemic on oncology care, 5 years later. Each doctor discussed a different aspect of multidisciplinary care, including medical oncology, radiation oncology, and epidemiology. CancerNetwork® spoke with leading clinicians including:  ·      Aditya Bardia, MD, MPH, FSCO, professor in the Department of Medicine, Division of Hematology/Oncology, and director of Translational Research Integration at the University of California Los Angeles Health Jonsson Comprehensive Cancer Center; ·      Ritu Salani, MD, director of Gynecologic Oncology at the University of California Los Angeles, and ONCOLOGY® editorial advisory board member; ·      Scarlett Lin Gomez, PhD, MPH, a professor in the Department of Epidemiology and Biostatistics at the University of California San Francisco (UCSF), and co-leader of the Cancer Control Program at UCSF Helen Diller Family Comprehensive Cancer Center ·      Marwan F. Fakih, MD, professor in the Department of Medical Oncology & Therapeutics Research, associate director for Clinical Sciences, medical director of the Briskin Center for Clinical Research, division chief of GI Medical Oncology, and co-director of the Gastrointestinal Cancer Program at City of Hope Comprehensive Cancer Center; ·      Elizabeth Zhang-Velten, MD, a radiation oncologist at Keck Medicine of University of Southern California;  ·      Frances Elain Chow, MD, neuro-oncologist at the University of Southern California (USC) Norris Comprehensive Cancer Center ·      James Yu, MD, MHS, FASTRO, assistant professor adjunct, Department of Radiation Oncology, Smilow Cancer Hospital at Saint Francis Hospital, and ONCOLOGY® editorial advisory board member.  The COVID-19 pandemic disrupted routine cancer care in a number of ways. Many patients were unable to receive timely screening, diagnosis, and treatment, Fakih noted. Additionally, Bardia stated that the pandemic led to a decrease in the number of patients participating in clinical trials. One of the most significant changes in oncology care, according to Salani, has been the increased use of telehealth. Telehealth has allowed patients to receive care from the comfort of their own homes, which has been especially beneficial for patients who live in rural areas or who have difficulty traveling. Telehealth has also made it easier for patients to connect with their doctors and to receive support from other members of their care team.  For Gomez, the COVID-19 pandemic also highlighted the importance of addressing the structural and social drivers of health. These are the conditions in which people are born, grow, live, work, and age that can affect their health. For example, people who live in poverty or who lack access to healthy food are more likely to develop cancer. The pandemic has led to a renewed focus on addressing these disparities. Overall, the COVID-19 pandemic has had a profound impact on oncology care. However, it has also led to a number of positive changes, such as the increased use of telehealth and the focus on addressing the structural and social drivers of health. In the years to come, it will be important to continue to build on these changes in order to improve the lives of patients with cancer.

This week, we welcome Dr. Amar Kishan to our show to discuss the role of radiation oncology in the management of patients with testicular cancer. As our listeners know by now, the management of patients with testicular cancer spans multiple specialities. We always appreciate hearing from our colleagues about their perspective.Episode contents:- What are important studies to send to radiation oncology prior to their appointment? - How radiation is planned for seminoma patients and a discussion of the treatment course- Implications on spermatogenesis, organ function, and infertility - Role of proton therapy?- Emerging therapies****Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

Strap in for a wild ride through the Medicare mess threatening radiation oncology in 2026. From a bizarre AMA survey that thinks we're just radiology's quirky cousin, to ASTRO's head-scratching distractions, we break down the...break down?Recorded at midnight in the Vermont Mountain Basements™, this episode unpacks the Byzantine world of CPT codes, RVUs, and a 40% practice expense gut punch that could turn off the lights. OOTB is produced by Photon Media.Contact: jason@becktamd.com

Dr. Sue Yom, Editor in Chief, hosts Dr. Kristin Hsieh, radiation oncology resident at Icahn School of Medicine at Mount Sinai and member of the SWRO mentorship committee; Dr. Crystal Seldon Taswell, Assistant Professor in the Department of Radiation Oncology at the University of Miami and past Chair of SWRO; Dr. Jennifer Croke, radiation oncologist at Princess Margaret Cancer Center and Associate Professor and Director of Fellowship at the University of Toronto; and Dr. Reshma Jagsi, the Lawrence W. Davis Professor and Chair of the Department of Radiation Oncology at at Emory University. All were co-authors on this month's featured publication, A 5-Year, Multi-Institutional Mentorship Program in Radiation Oncology: The Society for Women in Radiation Oncology Experience.

In this episode of the ACRO podcast CURiE edition, CURiE Disease Site Lead Dr. Jennifer Lee speaks with author Dr. Christopher Jahraus about his published article, "ACROPath Oligometastases: The American College of Radiation Oncology Clinical Pathway." ACROPath® is a major initiative of ACRO that aims to present aggregated clinical pathway data in a highly usable format that is readily accessible to clinicians at the point of care in real time. The oligometastases pathway is the first published algorithm in this collection, with additional pathways anticipated in future publications.Contemporary Updates: Radiotherapy Innovation & Evidence (CURiE) is the official publication platform of the American College of Radiation Oncology through the Cureus Journal of Medical Science.Read the article here: https://www.cureus.com/articles/290108-acropath-oligometastases-the-american-college-of-radiation-oncology-clinical-pathway

In this episode, we're joined by Dr. Daniel Indelicato and Dr. Rohan Deraniyagala, two distinguished experts whose work is transforming the landscape of pediatric oncology. With decades of combined experience and groundbreaking research, Danny and Rohan offer invaluable insights into the world of proton therapy. Listen as they unpack the distinct advantages of proton therapy, shedding light on why this method is especially beneficial for children by minimizing harmful side effects and enhancing quality of life post-treatment.The views expressed in this podcast are those of the interviewees. By listening to this, you agree not to use this podcast as medical advice to treat any medical condition in either yourself or others, including but not limited to patients that you are treating.  Consult your own physician for any medical issues that you may be having.  This entire disclaimer also applies to any guests or contributors to the podcast.  Under no circumstances shall Ion Beam Applications SA (IBA), any guests or contributors to the podcast, or any employees, associates, or affiliates of IBA be responsible for damages arising from use of the podcast.

The cost and quality of care can vary dramatically—even within the same health system. This has real ramifications for patients and clinicians, not to mention system outcomes. But reducing unwarranted variation in clinical care is much easier said than done. In 2019, UNC Health launched a care redesign office to take on the job. They identified 24 sources of variation to target. And their efforts were so successful that five years later, it was time to set their sights on a new list of targets—this time with a partner. In this episode, host Abby Burns invites Cyndi Hall, former Executive Director of Care Redesign at UNC Health, and Dr. Larry Marks, Executive Medical Director for Care Redesign, Professor of Radiation Oncology, and Assistant Dean of Organizational Health and Quality at UNC Health and School of Medicine, to break down the last five years of their care design work. They share how they selected which clinical areas to target, stories of what it means when this work is successful, and through it all, underscore the role of true change agents of this work: the clinicians themselves. Note: Cyndi Hall is now Senior Advisor for Healthcare Plus Solutions Group where she is translating her expertise in care variation reduction to help provider organizations improve the clinician onboarding process. Reducing clinical variation is something Advisory Board is actively researching in 2025. If CVR has been on your organization's docket and you have best practices to share, reach out to us at podcasts@advisory.com with the subject line “Sharing our CVR work” to get in touch with our research team. Links: 4 common pitfalls in care standardization — and how to overcome them Care variation reduction metric picklist UNC Health | Changing Lives for the Better Healthcare Leadership Training & Consulting | Healthcare Plus Solutions Obtaining Imaging Cost and Quality Information in Femoroacetabular Impingement: The Patient Experience - PMC Insights from the 2026 CMS Advance Notice How Steindler Orthopedic improved joint replacements with digital surgical technologies A transcript of this episode as well as more information and resources can be found on RadioAdvisory.advisory.com.

The cost and quality of care can vary dramatically—even within the same health system. This has real ramifications for patients and clinicians, not to mention system outcomes. But reducing unwarranted variation in clinical care is much easier said than done. In 2019, UNC Health launched a care redesign office to take on the job. They identified 24 sources of variation to target. And their efforts were so successful that five years later, it was time to set their sights on a new list of targets—this time with a partner. In this episode, host Abby Burns invites Cyndi Hall, former Executive Director of Care Redesign at UNC Health, and Dr. Larry Marks, Executive Medical Director for Care Redesign, Professor of Radiation Oncology, and Assistant Dean of Organizational Health and Quality at UNC Health and School of Medicine, to break down the last five years of their care design work. They share how they selected which clinical areas to target, stories of what it means when this work is successful, and through it all, underscore the role of true change agents of this work: the clinicians themselves. Note: Cyndi Hall is now Senior Advisor for Healthcare Plus Solutions Group where she is translating her expertise in care variation reduction to help provider organizations improve the clinician onboarding process. Reducing clinical variation is something Advisory Board is actively researching in 2025. If CVR has been on your organization's docket and you have best practices to share, reach out to us at podcasts@advisory.com with the subject line “Sharing our CVR work” to get in touch with our research team. Links: 4 common pitfalls in care standardization — and how to overcome them Care variation reduction metric picklist UNC Health | Changing Lives for the Better Healthcare Leadership Training & Consulting | Healthcare Plus Solutions Obtaining Imaging Cost and Quality Information in Femoroacetabular Impingement: The Patient Experience - PMC Insights from the 2026 CMS Advance Notice How Steindler Orthopedic improved joint replacements with digital surgical technologies A transcript of this episode as well as more information and resources can be found on RadioAdvisory.advisory.com.

Dr Akila Viswanathan speaks with Dr Robert Coppes from The University Medical Center Groningen, Dr David Jaffray from MD Anderson Cancer Center and Dr Helen McNair from The Royal Marsden NHS Foundation Trust Institute of Cancer Research to look ahead to the future of radiation oncology as they discuss how to improve decision making, incorporating artificial intelligence, adapt to new training methods, improve safety and sustainability and much more for Seminars in Radiation Oncology.

In this episode, Dr. Geo welcomes Dr. Jonathan Haas, Director of Radiation Oncology at NYU Grossman School of Medicine in Long Island, to discuss the latest advancements in stereotactic body radiation therapy (SBRT) for prostate cancer. Dr. Haas, a pioneer in CyberKnife radiation, shares the latest research, treatment options, and what's on the horizon for prostate cancer care.Episode Highlights:✔ SBRT & CyberKnife Technology – How high-dose, highly targeted radiation is replacing traditional 9-week radiation therapy.✔ New Developments – Research is underway to reduce SBRT treatment from five sessions to just two, making therapy even more convenient.✔ Prostate Motion & Radiation Accuracy – The prostate moves during treatment—learn how advanced imaging and AI-powered tracking compensate for movement to improve precision.✔ Androgen Deprivation Therapy (ADT) & SBRT – Not all patients may need ADT. New studies explore whether men with Gleason 4+3 can avoid hormone therapy.✔ Who is a Candidate? – Understanding the differences between Gleason 6, 7, 8, and 9 patients and who may benefit most from SBRT.✔ Side Effects & Risk Factors – Discussing common side effects like bladder bleeding (2%), rectal irritation (5%), erectile dysfunction (25% over 5 years), and strictures (2%).✔ Artificial Intelligence & Radiation Therapy – The RayStation AI system is now optimizing radiation planning, increasing precision, and making treatments more effective.✔ Choosing the Right Treatment Center – Why it's crucial to seek multidisciplinary care, get second opinions, and explore clinical trials for the best possible outcome.Takeaway: The landscape of prostate cancer treatment is evolving rapidly. If you or a loved one is considering radiation therapy, ask about SBRT, AI-driven imaging, and new clinical trials to ensure you receive the most advanced and effective care.Join Dr. Geo each week for expert insights, science-backed advice, and empowering conversations designed to help you live better with age. ----------------Thank you to our partnersThe ProLon 5-Day Fasting Mimicking Diet is a plant-based meal program designed to provide fasting benefits while allowing food intake. Developed by Dr. Valter Longo, it supports cellular renewal, fat loss, and metabolic health through low-calorie, pre-packaged meals that maintain the body in a fasting state.Special Offer: Thank you for listening, you can purchase the ProLon kit for just $148 by using this link.We'd also like to thank our partner AG1 by Athletic Greens. AG1 contains 75 high-quality vitamins, minerals, whole-food sourced ingredients, probiotics, and adaptogens to help you start your day right. This special blend of ingredients supports your gut health, nervous system, immune system, energy, recovery, focus, and aging. All the essentials in one scoop. Enjoy AG1 by Athletic Greens.----------------Thanks for listening to this week's episode. Subscribe to The Dr. Geo YouTube...

Check out this week's QuadCast as we highlight the role of staging brain MRI in metastatic breast cancer, the link between acute and late toxicity in prostate cancer treatment, the benefits of liver SBRT over TACE, and more. Check out the website and subscribe to the newsletter! www.quadshotnews.com Founders & Lead Authors: Laura Dover & Caleb Dulaney Podcast Host: Sam Marcrom

50 Years of Cancer Progress: Radiation Oncology with guest Dr. Peter Glazer February 9, 2025 Yale Cancer Center visit: http://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095

This episode of Lung Cancer Considered covers the recent FDA approval of Osimertinib after chemo-radiation in EGFR positive NSCLC based on the LAURA trial which was presented at the 2024 ASCO Annual Meeting. Host Dr. Narjust Florez goes in depth with podcast guest Dr. Pamela Samson about the LAURA Trial and its implications for patients and clinicians. Guest: Dr. Pamela Samson is an assistant professor in the Department of Radiation Oncology at Washington University in St. Louis. Dr. Samson specializes in the care of thoracic malignancies and ways to deliver appropriate radiation therapy without compromising efficacy and diminishing toxicities.

Our Editor-in-Chief Dr. Sue Yom co-hosts with Dr. Henning Willers, our journal's Biology Section Editor and Associate Professor of Radiation Oncology at Massachusetts General Hospital. Guests are Dr. Simon Powell, Chair of Memorial Sloan Kettering Cancer Center Department of Radiation Oncology, who joins us as the co-last author of a new publication, Increased synthetic cytotoxicity of combinatorial chemoradiotherapy in homologous recombination deficient tumors, and Dr. Kerstin Borkmann, Professor of Radiobiology at the University Clinic Hamburg Eppendorf and Biology Associate Editor for our journal. She is the co-author of the accompanying editorial, BRCAness identifies synthetic cytotoxicity between cisplatin and RT.

Check out this week's QuadCast as we highlight the results of RTOG 0920 for adjuvant therapy in H&N cancer, the benefit of bone protective agents in patients receiving radium 223 + enzalutamide, the benefit of incorporating counseling into smoking cessation strategies, and more. Check out the website and subscribe to the newsletter! www.quadshotnews.com Founders & Lead Authors: Laura Dover & Caleb Dulaney Podcast Host: Sam Marcrom

Workup and management of HCC in Radiation Oncology featuring guest Dr Judy Lubas

Dr. Sue Yom, Editor in Chief, hosts guests Dr. Cristian Udovicich, a Fellow in Radiation Oncology at the University of Toronto's Sunnybrook Odette Cancer Centre, and Dr. Angela Jia, Assistant Professor and Assistant Residency Program Director at University Hospitals Cleveland Medical Center, who were the first and second authors of "Evolving Paradigms in Prostate Cancer: The Integral Role of Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Primary Staging and Therapeutic Decision-Making." In addition, we review long-term SBRT results with Dr. Andrew Loblaw, Full Professor in the Department of Radiation Oncology and Institute of Health Policy, Management and Evaluation at Sunnybrook Health Science Center at the University of Toronto and supervising author of "Stereotactic Radiation Therapy for Localized Prostate Cancer: 10-Year Outcomes From Three Prospective Trials," and Dr. Constantinos Zamboglou, Deputy Medical Director at the German Oncology Center in Limassol, Cyprus and first author of an accompanying editorial, "Stereotactic Body Radiotherapy for Prostate Cancer is Getting Mature: 10-Year Outcomes From Three Prospective Trials."

Check out this week's QuadCast as we highlight ideal adjuvant management of endometrial cancer from GOG 258, the best approach to locally recurrent rectal cancer, and also highlight recurrent GBM management guidelines. Welcome to 2025! Check out the website and subscribe to the newsletter! www.quadshotnews.com Founders & Lead Authors: Laura Dover & Caleb Dulaney Podcast Host: Sam Marcrom

In this episode, Scott Becker speaks with Dr. Sagar Patel, Radiation Oncologist at Saint Francis Healthcare System. Dr. Patel shares his journey from Ivy League training to leading innovative cancer care in a semi-rural community, discusses the art and science of radiation oncology, and explores strategies for bringing high-quality healthcare to underserved regions.

This podcast discussed the topic of "Improving consistency and reducing human bias for physicians' target contouring using AI auto-segmentation." Experts joining the discussion include Steve Jiang, PhD, Professor and Vice Chair in Department of Radiation Oncology at University of Texas Southwestern and Director of Medical Artificial Intelligence and Automation Lab, Nathan Yu, MD, Assistant Professor in Department of Radiation Oncology, Mayo Clinic Arizona, and Yi Rong, PhD, Professor and Lead photon physicist in Department of Radiation Oncology at Mayo Clinic Arizona. This podcast focused on the utility of AI in automatic segmentation of medical imaging and the challenges related to physician variability in clinical practice. We discussed various strategies for addressing these challenges, including developing physician-style aware AI models and balancing standardization with personalization in AI tool development and deployment. The emphasis is on the feasibility and clinical utility of using AI to improve the accuracy and efficiency of medical image segmentation while respecting the art and personalization inherent in clinical medicine.

This podcast discussed the topic of "Improving consistency and reducing human bias for physicians' target contouring using AI auto-segmentation." Experts joining the discussion include Steve Jiang, PhD, Professor and Vice Chair in Department of Radiation Oncology at University of Texas Southwestern and Director of Medical Artificial Intelligence and Automation Lab, Nathan Yu, MD, Assistant Professor in Department of Radiation Oncology, Mayo Clinic Arizona, and Yi Rong, PhD, Professor and Lead photon physicist in Department of Radiation Oncology at Mayo Clinic Arizona. This podcast focused on the utility of AI in automatic segmentation of medical imaging and the challenges related to physician variability in clinical practice. We discussed various strategies for addressing these challenges, including developing physician-style aware AI models and balancing standardization with personalization in AI tool development and deployment. The emphasis is on the feasibility and clinical utility of using AI to improve the accuracy and efficiency of medical image segmentation while respecting the art and personalization inherent in clinical medicine.

Check out this week's QuadCast where we highlight the benefits of considering short course RT instead of years of endocrine therapy for low risk breast cancer patients, the superiority of SBRT over ablation for recurrent HCC, and much more! Check out the website and subscribe to the newsletter! www.quadshotnews.com Founders & Lead Authors: Laura Dover & Caleb Dulaney Podcast Host: Sam Marcrom

Check out this week's QuadCast as we highlight the oncologic benefit of extended nodal dissection for prostate cancer, the comparison of Durvalumab and Cetuximab in cisplatin-ineligible H&N cancer patients, the high incidence of psoriasis development on immunotherapy, and more. Check out the website and subscribe to the newsletter! www.quadshotnews.com Founders & Lead Authors: Laura Dover & Caleb Dulaney Podcast Host: Sam Marcrom